Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GELS NASDAQ:MRSN NASDAQ:MURA NASDAQ:SNTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGELSGelteq$1.38-11.5%$1.58$0.77▼$5.50$14.72MN/A3.79 million shs424,832 shsMRSNMersana Therapeutics$7.66+8.8%$7.53$5.21▼$70.75$35.13M0.8788,778 shs65,974 shsMURAMural Oncology$2.08+0.5%$2.17$0.95▼$4.74$35.86M3496,072 shs252,474 shsSNTISenti Biosciences$1.30-1.5%$1.76$1.26▼$16.94$34.53M2.06121,410 shs134,620 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGELSGelteq-11.54%+15.00%-16.87%-41.03%+137,999,900.00%MRSNMersana Therapeutics+8.81%+9.12%+21.59%-19.45%-79.57%MURAMural Oncology+0.48%0.00%+30.82%-18.75%-31.35%SNTISenti Biosciences-1.52%-9.09%-17.72%-53.74%-55.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGELSGelteq$1.38-11.5%$1.58$0.77▼$5.50$14.72MN/A3.79 million shs424,832 shsMRSNMersana Therapeutics$7.66+8.8%$7.53$5.21▼$70.75$35.13M0.8788,778 shs65,974 shsMURAMural Oncology$2.08+0.5%$2.17$0.95▼$4.74$35.86M3496,072 shs252,474 shsSNTISenti Biosciences$1.30-1.5%$1.76$1.26▼$16.94$34.53M2.06121,410 shs134,620 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGELSGelteq-11.54%+15.00%-16.87%-41.03%+137,999,900.00%MRSNMersana Therapeutics+8.81%+9.12%+21.59%-19.45%-79.57%MURAMural Oncology+0.48%0.00%+30.82%-18.75%-31.35%SNTISenti Biosciences-1.52%-9.09%-17.72%-53.74%-55.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGELSGelteq 0.00N/AN/AN/AMRSNMersana Therapeutics 3.00Buy$56.60638.90% UpsideMURAMural Oncology 2.50Moderate Buy$12.00476.92% UpsideSNTISenti Biosciences 3.00Buy$8.50553.85% UpsideCurrent Analyst Ratings BreakdownLatest GELS, SNTI, MURA, and MRSN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025MRSNMersana TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$250.00 ➝ $36.008/14/2025MRSNMersana TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$125.00 ➝ $30.008/13/2025MRSNMersana TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.008/8/2025SNTISenti BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.006/12/2025SNTISenti BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGELSGelteqN/AN/AN/AN/A$1.30 per shareN/AMRSNMersana Therapeutics$40.50M0.94N/AN/A($1.92) per share-3.99MURAMural OncologyN/AN/AN/AN/A$8.22 per shareN/ASNTISenti Biosciences$2.56M13.28N/AN/A$5.31 per share0.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGELSGelteq-$2.33MN/A0.00∞N/AN/AN/AN/AN/AMRSNMersana Therapeutics-$69.19M-$14.62N/AN/AN/A-212.94%-990.16%-54.85%11/12/2025 (Estimated)MURAMural Oncology-$128.51M-$8.59N/AN/AN/AN/A-107.76%-87.57%11/12/2025 (Estimated)SNTISenti Biosciences-$52.79M-$8.95N/AN/AN/AN/A-223.98%-76.02%11/13/2025 (Estimated)Latest GELS, SNTI, MURA, and MRSN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025MRSNMersana Therapeutics-$3.75-$4.08-$0.33-$4.87$6.06 million$3.06 million8/7/2025Q2 2025SNTISenti Biosciences-$0.58-$0.56+$0.02-$0.56$1.30 million$0.50 million8/4/2025Q2 2025MURAMural Oncology-$1.13-$1.77-$0.64-$2.78N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGELSGelteqN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/AMURAMural OncologyN/AN/AN/AN/AN/ASNTISenti BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGELSGelteqN/A0.79N/AMRSNMersana TherapeuticsN/A1.351.35MURAMural OncologyN/A2.872.87SNTISenti BiosciencesN/A3.263.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGELSGelteqN/AMRSNMersana Therapeutics93.92%MURAMural Oncology80.21%SNTISenti Biosciences25.73%Insider OwnershipCompanyInsider OwnershipGELSGelteqN/AMRSNMersana Therapeutics13.00%MURAMural Oncology2.20%SNTISenti Biosciences3.12%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGELSGelteqN/A9.44 millionN/AN/AMRSNMersana Therapeutics1504.99 million4.34 millionOptionableMURAMural Oncology11917.32 million16.94 millionOptionableSNTISenti Biosciences426.16 million25.34 millionNot OptionableGELS, SNTI, MURA, and MRSN HeadlinesRecent News About These CompaniesSenti Bio to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | globenewswire.comSenti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTechAugust 14, 2025 | globenewswire.comSenti Biosciences Discusses Phase 2 Dose Selection for SENTI-202 in Virtual Investor SegmentAugust 12, 2025 | quiverquant.comQSenti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid LeukemiaAugust 12, 2025 | globenewswire.comSenti Biosciences, Inc.: Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML ...August 8, 2025 | finanznachrichten.deSenti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025August 7, 2025 | globenewswire.comSenti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid LeukemiaAugust 5, 2025 | globenewswire.comSenti Biosciences Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand ConferenceJuly 23, 2025 | finance.yahoo.comSenti Biosciences Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand ConferenceJuly 22, 2025 | globenewswire.comSenti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience ForumJuly 21, 2025 | globenewswire.comSenti Biosciences, Inc. Appoints Bryan Baum to Board of DirectorsJuly 18, 2025 | quiverquant.comQSenti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of DirectorsJuly 18, 2025 | globenewswire.comNASDAQ:SNTI Financials | Senti Biosciences Inc - Investing.comJuly 3, 2025 | investing.comSNTI - Senti Biosciences Inc Sustainability - MorningstarJuly 2, 2025 | morningstar.comMSenti Biosciences CEO Timothy Lu Highlights Advancements in Gene Circuit Technology at Nasdaq’s Amplify Spotlight SeriesJune 30, 2025 | quiverquant.comQSenti Bio Participates in Nasdaq Amplify Spotlight SeriesJune 30, 2025 | globenewswire.comSenti Biosciences, Inc. to Present at 2025 SEED Conference on Tumor-Specific Therapies - NasdaqJune 26, 2025 | nasdaq.comSenti Biosciences, Inc. to Present at 2025 SEED Conference on Tumor-Specific TherapiesJune 24, 2025 | quiverquant.comQSenti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) ConferenceJune 24, 2025 | globenewswire.comSenti Biosciences, Inc. Reports Progress in Phase 1 Trial of SENTI-202 for Acute Myeloid Leukemia, Receives Orphan Drug DesignationJune 18, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGELS, SNTI, MURA, and MRSN Company DescriptionsGelteq NASDAQ:GELS$1.38 -0.18 (-11.54%) As of 09/9/2025 04:00 PM EasternGelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.Mersana Therapeutics NASDAQ:MRSN$7.66 +0.62 (+8.81%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$7.48 -0.18 (-2.34%) As of 04:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.Mural Oncology NASDAQ:MURA$2.08 +0.01 (+0.48%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$2.08 0.00 (-0.24%) As of 09/9/2025 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.Senti Biosciences NASDAQ:SNTI$1.30 -0.02 (-1.52%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$1.32 +0.02 (+1.54%) As of 04:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
